Skip to main content
STRIDES PHARMA SCIENCE LIMITED logo

STRIDES PHARMA SCIENCE LIMITED — Investor Relations & Filings

Ticker · STAR ISIN · INE939A01011 LEI · 335800WHFYXUCHR9DD10 BSE.NS Manufacturing
Open in API
Filings indexed 1,200 across all filing types
Latest filing 2023-09-07 Capital/Financing Update
Country IN India
Listing BSE.NS STAR

About STRIDES PHARMA SCIENCE LIMITED

https://www.strides.com

Strides Pharma Science Limited is a global pharmaceutical organization focused on the development and manufacture of IP-led niche finished dosage formulations. The company’s product portfolio encompasses a wide range of therapeutic areas, specializing in complex oral solids, softgel capsules, topicals, and liquids. It maintains a significant presence in highly regulated markets, including the United States, Europe, and Australia, while also serving institutional and emerging markets. The company operates multiple manufacturing facilities globally, many of which are approved by major international regulatory agencies such as the USFDA. Strides emphasizes research and development to drive innovation in specialized delivery systems and difficult-to-manufacture products, positioning itself as a key player in the global generic pharmaceutical landscape.

Recent filings

Filing Released Lang Actions
Restructuring
Capital/Financing Update Classification · 95% confidence The document is an official communication addressed to stock exchanges regarding an internal restructuring transaction approved by the Board of Directors. It details the acquisition of 100% shareholding in a subsidiary company, Strides Pharma Services Private Limited, from another wholly owned subsidiary. The document includes disclosures required under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which pertains to material events or information. The content focuses on the announcement of a corporate transaction (acquisition and divestment within group entities) and provides detailed information about the transaction, parties involved, consideration, and regulatory compliance. There are no financial statements or comprehensive financial performance data presented, so it is not an Annual Report, Interim Report, or Earnings Release. It is not a Board/Management change announcement, nor a voting result or dividend notice. The document is a regulatory announcement about a capital restructuring transaction within the group, specifically an acquisition. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length (7636 characters) and detailed transaction disclosure support this classification with high confidence.
2023-09-07 English
Loss of Share Certificates
Regulatory Filings Classification · 95% confidence The document is an official communication addressed to stock exchanges regarding a shareholder's request for issuance of a duplicate share certificate due to loss of securities. It references compliance with SEBI regulations and includes details about the shareholder and share certificates. There are no financial statements, earnings data, or management discussion. The document is an announcement of a corporate action related to share certificates, specifically the issuance of duplicate certificates, which falls under regulatory compliance and shareholder communication. It is not a financial report, earnings release, or management report. Therefore, the most appropriate classification is Regulatory Filings (RNS), as it is a regulatory announcement that does not fit into more specific categories.
2023-09-06 English
Resignation
Board/Management Information Classification · 100% confidence The document is a formal notification addressed to stock exchanges about the resignation of a senior management personnel, Mr. Ankit Gupta, from his position as Vice President and Head of Corporate Development and Strategy. It includes a resignation letter and details about the cessation of employment. There are no financial statements, earnings data, or report publications. The content clearly relates to a change in senior management. Therefore, the document fits the category of Board/Management Information (MANG). The document length is 3619 characters, which is consistent with a management change announcement rather than a full report or regulatory filing.
2023-09-01 English
Shareholders meeting
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is an official communication addressed to stock exchanges regarding the outcome of the 32nd Annual General Meeting (AGM) of Strides Pharma Science Limited held on August 28, 2023. It includes detailed voting results for various resolutions passed at the AGM, such as adoption of audited financial statements, declaration of dividend, re-appointment of directors, payment of commissions, and remuneration matters. The document references compliance with SEBI Listing Regulations and includes annexures with voting results and scrutinizer reports. The content is focused on the announcement of voting outcomes and related disclosures following the AGM, rather than the AGM materials themselves or the full annual report. Therefore, this document fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is substantial and contains detailed voting data, confirming it is not a mere announcement of report publication or a short notice. Hence, the classification is DVA with high confidence.
2023-08-30 English
Press Release
Regulatory Filings Classification · 95% confidence The document is a press release announcing that Strides Pharma Science Limited has received USFDA approval for a specific pharmaceutical product. It contains no financial statements, regulatory certifications, or detailed financial data. The document is relatively short (4242 characters) and serves as a public announcement of a corporate event (product approval). It does not fit into categories like Annual Report, Earnings Release, or Regulatory Filings. The content is clearly a press release about a product approval, which aligns with Capital/Financing Update (CAP) as it relates to company product and market position updates, but more precisely it is a press release about a regulatory approval rather than financing. Since there is no specific category for press releases, the closest fitting category is Regulatory Filings (RNS) as a general regulatory announcement. However, given the nature of the announcement (product approval), and the absence of financial or capital structure changes, the best fit is Regulatory Filings (RNS).
2023-08-30 English
Loss of Share Certificates
Regulatory Filings Classification · 95% confidence The document is a formal communication addressed to stock exchanges regarding the issuance of a duplicate share certificate due to loss of securities by a shareholder. It references compliance with SEBI regulations and includes details about the shareholder and share certificates. There are no financial statements, earnings data, management discussion, or other report content. The document is an announcement or intimation related to share certificates and shareholder records, not a financial report or meeting material. It is also relatively short (3018 characters) and serves as a regulatory notification to exchanges. Therefore, it fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2023-08-29 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.